Previous studies have reported that patients with malignancy have significantly decreased levels of NKA-IFNγ compared to healthy subjects [8, 9], suggesting that NKA-IFNγ might be useful as a supportive diagnostic marker of malignancy. This evidence concerns the gene IFNG and cancer.